Oct 17 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N :
* HEALTH CANADA HAS APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), THE FIRST SGLT2 INHIBITOR IN CANADA TO RECEIVE THIS INDICATION(1)
* JANSSEN PHARMACEUTICAL SAYS HEALTH CANADA APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS